Amgen Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Amgen Inc. stock analysis AMGN overview
Neutral -5

Amgen (AMGN) Stock Slides as Market Rises: Facts to Know Before You Trade

📉 Amgen stock closed at $344.55, dropping 1.17% despite the S&P 500 rising 0.8%.

📈 The biotech leader has lost 1.29% over the past month, underperforming both the Medical sector and the broader market.

📅 Earnings are scheduled for release on April 30, 2026, with analysts projecting $4.75 per share in EPS.

📊 Expected earnings represent a 3.06% year-over-year decline compared to the previous period.

💰 Analysts forecast net sales of $8.49 billion for the upcoming quarter, marking a 4.16% increase.

🧮 Full-year consensus estimates project earnings of $22.18 per share and revenue of $37.81 billion.

📉 Recent EPS projection changes show a 0.66% decrease in consensus over the last 30 days.

⚖️ Amgen's current Forward P/E ratio is 15.72, which trades at a discount to the industry average of 21.28.

📏 The stock carries a PEG ratio of 3.64, significantly higher than the industry average of 1.49.

🔝 Amgen currently holds a Zacks Rank of #3 (Hold), positioned as neither a strong buy nor sell.

🏭 The company belongs to the Medical - Biomedical and Genetics industry, ranked in the top 40% of all sectors.

Bullish Signals
  • Amgen's upcoming earnings report on April 30, 2026, is expected to show revenue growth of 4.16%, with analysts projecting net sales of $8.49 billion, which would be a year-over-year increase.
  • The Zacks Consensus Estimates forecast full-year earnings of $22.18 per share and revenue of $37.81 billion, indicating positive growth of +1.56% and +2.88%, respectively, compared to the previous year.
  • Amgen is trading at a Forward P/E ratio of 15.72, which represents a discount compared to its industry average Forward P/E of 21.28, suggesting potential valuation upside.
  • The Medical - Biomedical and Genetics industry in which Amgen operates holds a Zacks Industry Rank of 96, positioning it in the top 40% of all industries according to Zacks Investment Research.
  • Research indicates that industries with higher Zacks ranks outperform lower-rated groups significantly, with top 50% rated industries outperforming the bottom half by a factor of 2 to 1.
Risk Factors
  • Amgen's stock declined by -1.17% in the latest session, underperforming the S&P 500 which gained 0.8%.
  • The company has depreciated by 1.29% over the past month while the broader market saw an 8.11% gain in the S&P 500.
  • Analysts expect upcoming earnings on April 30, 2026 to show a year-over-year earnings decline of 3.06%.
  • The consensus EPS projection for Amgen has moved 0.66% lower within the past 30 days, indicating negative short-term momentum.
  • Amgen currently holds a Zacks Rank of #3 (Hold), which is below the top-rated #1 or #2 categories associated with strong buy ratings.
  • The company's PEG ratio stands at 3.64, which is significantly higher than the industry average PEG ratio of 1.49 for the Medical - Biomedical and Genetics industry.
  • Amgen trades at a Forward P/E of 15.72, yet investors should note that this valuation metric must be viewed in the context of potential earnings contraction risks.
Full Analysis
Amgen Inc. (AMGN) shares declined by 1.17% to close at $344.55, lagging behind the broader market as the S&P 500 gained 0.8% and the Nasdaq rose 1.63%. Over the past month, Amgen's stock has depreciated by 1.29%, underperforming both the Medical sector's loss of 0.32% and the S&P 500's gain of 8.11%. Despite the recent slide, the company is positioned with a Forward P/E ratio of 15.72, which is lower than its industry average of 21.28, suggesting it trades at a discount relative to peers. However, the stock carries a PEG ratio of 3.64, significantly higher than the Medical - Biomedical and Genetics industry average of 1.49, indicating that market expectations for earnings growth may be priced in or that current growth prospects are viewed more conservatively by analysts. Market attention is focused on Amgen's upcoming earnings release scheduled for April 30, 2026. Analysts currently expect quarterly earnings of $4.75 per share, representing a year-over-year decline of 3.06%, while projecting net sales of $8.49 billion, an increase of 4.16% from the previous period. On a full-year basis, consensus estimates forecast earnings of $22.18 per share and revenue of $37.81 billion, reflecting modest growth of +1.56% and +2.88% respectively compared to the prior year. Recent adjustments to analyst estimates have seen the consensus EPS projection move 0.66% lower over the past 30 days, contributing to the stock's current Zacks Rank of #3 (Hold). According to Zacks Investment Research methodology, estimate revisions are closely linked to near-term share price momentum. The company operates within an industry ranked in the top 40% of all 250+ industries based on its average Zacks Rank, with research suggesting that top-rated industries historically outperform the bottom half by a factor of two to one. The #1-ranked stocks in the Zacks system have demonstrated a track record of outperforming the S&P 500 since 1988, delivering an average annual gain of +25%. Investors are advised to monitor these metrics as earnings season approaches, particularly given the divergence between valuation multiples and current earnings trajectory expectations for the biotech giant.